Dr. Zhu has more than 20 years of pharma industry experience and worked with both global pharmaceutical companies (Pfizer and JNJ) and Chinese pharmaceutical companies (Betta Pharma and SciClone Pharmaceuticals). He has done 40 strategic transactions (total value > US$17.8 billion) including the most recent 4 ADC out-licensing deals to Biohaven and AimedBio that he executed within 6 months after he joined GeneQuantum Healthcare in Suzhou in early 2024, setting up a record for the most # of deals done by a Chinese ADC company in a year. Prior to that, he led the transaction to set up the Amgen-Betta joint venture to commercialize Amgen’s Vectibix in China, the acquisition of Ensartinib which was approved in 2020 and became the 2nd leading product for Betta, and the in-license of 2 US approved products in 18 moths by SciClone from Menarinis, Vaborem (meropenem/vaborbactam) and Elacestrant -- the world's first approved oral SERD for ER+/HER2- breast cancer. Elacestrant has the potential to become SciClone's next blockbuster following Zadaxin®. Dr. Zhu returned to China in 2009 after 16 years in US where he served as the Senior business development Manager at Esperion Therapeutics which was acquired by Pfizer for US$1.3 billion in 2003.